These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 29891182)

  • 1. Safety of Direct Oral Anticoagulants and Vitamin K Antagonists in Oldest Old Patients: A Prospective Study.
    Rodríguez-Pascual C; Torres-Torres I; Gómez-Quintanilla A; Ferrero-Martínez AI; Sharma J; Guitián A; Basalo MC; Montero-Magan M; Vilches-Moraga A; Olcoz-Chiva MT; Paredes-Galán E; Rodríguez-Artalejo F
    J Am Med Dir Assoc; 2018 Nov; 19(11):936-941. PubMed ID: 29891182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
    Deitelzweig S; Bruno A; Trocio J; Tate N; Gupta K; Lin J; Lingohr-Smith M
    Curr Med Res Opin; 2016; 32(3):573-82. PubMed ID: 26652179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data.
    Enomoto A; Mano Y; Kawano Y; Nishikawa T; Aoyama T; Sasaki Y; Nagata M; Takahashi H
    Biol Pharm Bull; 2021; 44(9):1294-1302. PubMed ID: 34471057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry).
    Sotomi Y; Hirata A; Amiya R; Kobayashi T; Hirayama A; Sakata Y; Higuchi Y
    Am J Cardiol; 2019 Apr; 123(8):1293-1300. PubMed ID: 30717887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Anticoagulation in Patients in the Emergency Department: High Rates of Off-Label Doses, No Difference in Bleeding Rates.
    Eschler CM; Woitok BK; Funk GC; Walter P; Maier V; Exadaktylos AK; Lindner G
    Am J Med; 2020 May; 133(5):599-604. PubMed ID: 31668901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
    Vinogradova Y; Coupland C; Hill T; Hippisley-Cox J
    BMJ; 2018 Jul; 362():k2505. PubMed ID: 29973392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
    Briere JB; Bowrin K; Coleman C; Fauchier L; Levy P; Folkerts K; Toumi M; Taieb V; Millier A; Wu O
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):27-36. PubMed ID: 30169975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population.
    Cerdá M; Cerezo-Manchado JJ; Johansson E; Martínez F; Fernández M; Varela A; Rodríguez S; Bosch F; Santamaría A
    J Comp Eff Res; 2019 Feb; 8(3):165-178. PubMed ID: 30654626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of DOACs vs acenocoumarol in patients undergoing catheter ablation of atrial fibrillation.
    Vlachos K; Efremidis M; Bazoukis G; Letsas KP; Saplaouras A; Georgopoulos S; Karamichalakis N; Rokiza A; Sakellaropoulou A; Kolokathis AM; Efremidis T; Asvestas D; Sideris A
    Clin Cardiol; 2017 Oct; 40(10):847-852. PubMed ID: 28561951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: The NOAC-TURK study.
    Gedikli Ö; Altay S; Ünlü S; Çakmak HA; Aşkın L; Yanık A; Beşli F; Sinan ÜY; Canpolat U; Şahin M; Pehlivanoğlu S
    Anatol J Cardiol; 2021 Mar; 25(3):196-204. PubMed ID: 33690135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of bleeding complications due to oral anticoagulant drugs].
    Riess H
    Laryngorhinootologie; 2015 Oct; 94(10):697-709. PubMed ID: 26468622
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
    Malec K; Góralczyk T; Undas A
    Thromb Res; 2017 Apr; 152():93-97. PubMed ID: 27989533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin
.
    Adachi T; Hoshino H; Takagi M; Fujioka S;
    Cerebrovasc Dis Extra; 2017; 7(1):62-71. PubMed ID: 28376486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.